PPLPHARMA vs SYNCOMF: Stock Comparison
PIRAMAL PHARMA is the larger company by market capitalisation. PIRAMAL PHARMA shows a lower P/E and faster revenue growth, while SYNCOM FORMU (I) shows a higher ROE, a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
PPLPHARMA leads 3; SYNCOMF leads 8 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | PPLPHARMA | SYNCOMF |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | PPLPHARMA | SYNCOMF |
|---|---|---|
| Live Price | ₹229.95 | ₹20.41 |
| Day Change | -0.36% | 0% |
| Volume | 21,577 | 9,637 |
| 52-Week High | ₹239.54 | ₹27.49 |
| 52-Week Low | ₹132.3 | ₹10.21 |
| Distance from 52W High | -4% | -25.75% |
Valuation
| Metric | PPLPHARMA | SYNCOMF |
|---|---|---|
| Market Cap | ₹30,701 Cr | ₹1,920 Cr |
| P/E Ratio | 0x | 22.45x |
| P/B Ratio | 3.76x | 4.63x |
| EPS | ₹-0.52 | ₹0.26 |
| Book Value | ₹61.31 | ₹4.41 |
| Dividend Yield | 0% | 0.49% |
Growth
| Metric | PPLPHARMA | SYNCOMF |
|---|---|---|
| Revenue Growth (TTM YoY) | -0.1% | -9% |
| EPS Growth (TTM YoY) | 0% | 68.8% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | PPLPHARMA | SYNCOMF |
|---|---|---|
| ROE | 8.6% | 18.43% |
| ROCE | 9.1% | 18.63% |
| Net Margin | -3.68% | 15.63% |
| Operating Margin | 20.01% | 20.89% |
| Debt to Equity | 0.09x | 0x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | PPLPHARMA | SYNCOMF |
|---|---|---|
| Promoter Holding | 34.8% | 50.57% |
| FII Holding | 13.65%▲ 1.13 pp | 2.22%▲ 1.87 pp |
| DII Holding | 14.44%▼ 0.13 pp | 0% |
| Public Holding | 36.71%▼ 0.92 pp | 47.2%▼ 1.88 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: PIRAMAL PHARMA and SYNCOM FORMU (I).
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.